George A. Yendewa, John McLeod Griffiss, Wesley A. Gray, Amanda Healen, Howard M. Proskin, Scott A. Fulton, . . . Robert A. Salata. (2022). Dosing Colistimethate Every 8 h Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers. MDPI AG.
Chicago Style (17th ed.) CitationGeorge A. Yendewa, et al. Dosing Colistimethate Every 8 H Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing Without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers. MDPI AG, 2022.
MLA (9th ed.) CitationGeorge A. Yendewa, et al. Dosing Colistimethate Every 8 H Results in Higher Plasma Concentrations of Active Colistin Than Every 12-Hourly Dosing Without Increase in Nephrotoxicity: A Phase 1 Pharmacokinetics Trial in Healthy Adult Volunteers. MDPI AG, 2022.